Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

NCT06351748 · Completed

Last updated 2026-05-28

This study is observing how well the diabetes medication semaglutide (Ozempic) works in real-world settings for adults with type 2 diabetes.

Status Completed The study has finished.

Type Observational

Participants 34,238 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-01 · est. completion 2024-03

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06351748 ↗

Description as written by the study sponsor.

This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China\] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.

Treatments tested

Semaglutide also known as Ozempic Drug

Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.

Main thing measured	Change in Haemoglobin A1c (HbA1c) level
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06351748 ↗